A single and multiple dose study to assess blood and urine drug levels of fostamatinib in healthy Japanese subjects

Exclusion Criteria

• - History or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders
• - Any clinically significant illness, acute infection, known inflammatory process, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product
• - Smoking in excess of 5 cigarettes per day or equivalent within 30 days of Day 1
• - Use of prescription or over-the-counter drugs within 2 weeks of first administration of investigational product
• - Previous participation in a fostamatinib study